Last reviewed · How we verify
NCT06714032: COVID-19
Effect of Traditional Chinese Medicine of Severe COVID-19
Phase 3 trial testing TCM plus conventional drug in Severe COVID-19 in 172 participants. Completed in 25 January 2024.
8 November 2023
Quick facts
| Lead sponsor | Henan University of Traditional Chinese Medicine |
|---|---|
| Phase | Phase 3 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 172 |
| Start date | 29 January 2023 |
| Primary completion | 8 November 2023 |
| Estimated completion | 25 January 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- TCM plus conventional drug — full drug profile →
- TCM placebo plus conventional drug
Conditions studied
- Severe COVID-19 — all drugs for Severe COVID-19 →
Sponsor
Henan University of Traditional Chinese Medicine
Who can join
18 and older, any sex, with Severe COVID-19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study evaluated the effect of integrated traditional Chinese and Western medicine in the treatment of Severe COVID-19. The patients were randomly divided into experimental group and control group.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06714032
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of TCM plus conventional drug
Trials testing the same drug.
- NCT03185923 — Effect of Traditional Chinese Medicine on Outcomes in Patients With Severe Pneumonia · Phase 3 · unknown
Other recruiting trials for Severe COVID-19
Currently open trials in the same condition.
- NCT05233605 — Impact of Post-ARDS Covid-19 Sedation on Persistent Neuroinflammation · recruiting
Other Henan University of Traditional Chinese Medicine trials
Trials by the same sponsor.
- NCT07352488 — Modified Shenling Baizhu Powder for Allergic Asthma With Spleen Deficiency and Dampness Accumulation Syndrome · NA · not yet recruiting
- NCT07206745 — A Study on Integrated Chinese and Western Medicine for Severe Pneumonia Caused by Multidrug-Resistant Gram-Negative Bact · NA · not yet recruiting
- NCT07178392 — Disease-syndrome Characteristics of IPF · not yet recruiting
- NCT07162870 — Idiopathic Pulmonary Fibrosis Cohort of TCM · not yet recruiting
- NCT06914713 — Jin-shui Huan-xian Formula for Retarding the Decline of Pulmonary Function in IPF · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06714032 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Henan University of Traditional Chinese Medicine
- Last refreshed: 3 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06714032.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing